Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.64B P/E 32.22 EPS this Y 33.20% Ern Qtrly Grth 48.00%
Income 281.59M Forward P/E 11.74 EPS next Y 23.60% 50D Avg Chg 16.00%
Sales 829.25M PEG 0.42 EPS past 5Y 84.82% 200D Avg Chg -2.00%
Dividend N/A Price/Book 85.70 EPS next 5Y 25.00% 52W High Chg -28.00%
Recommedations 2.20 Quick Ratio 5.07 Shares Outstanding 127.05M 52W Low Chg 44.00%
Insider Own 1.08% ROA 11.89% Shares Float 125.47M Beta 1.26
Inst Own 100.48% ROE 222.07% Shares Shorted/Prior 7.89M/8.08M Price 42.85
Gross Margin 67.59% Profit Margin 33.96% Avg. Volume 1,156,193 Target Price 51.11
Oper. Margin 45.01% Earnings Date May 7 Volume 979,812 Change 1.35%
About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics, Inc. News
04/24/24 Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
04/23/24 Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
04/23/24 Halozyme to Report First Quarter 2024 Financial and Operating Results
04/18/24 Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
04/18/24 Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
04/05/24 Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
04/04/24 Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
04/04/24 Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?
03/29/24 Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
03/29/24 The 3 Best Biotech Stocks to Buy in Q2 2024
03/28/24 Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
03/27/24 Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
03/21/24 Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
03/20/24 Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
03/19/24 Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
03/14/24 Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ...
03/13/24 7 Biotech Stocks to Buy as Sector Rotation Ramps Up
03/12/24 Should You Hold Halozyme Therapeutics (HALO)?
02/27/24 Halozyme to Participate in Upcoming Investor Conferences
02/23/24 Analyst Estimates: Here's What Brokers Think Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) After Its Full-Year Report
HALO Chatroom

User Image Stock_Titan Posted - 1 day ago

$HALO Halozyme to Report First Quarter 2024 Financial and Operating Results https://www.stocktitan.net/news/HALO/halozyme-to-report-first-quarter-2024-financial-and-operating-alflrdsjk0pv.html

User Image NoobyDoo Posted - 5 days ago

$HALO News coming next week? 🤔🤞 Strength and volume into the close! $HALO

User Image Doozio Posted - 5 days ago

$xbi literally da YUGEST piece of 💩 until a 🧠 $dawn becomes 🧠⏰ n da $halo makes it obvious! Chop chop huckleberries….. whut ⏰? https://youtu.be/Dol10tMdScg?si=42EYbR71AmHOEZJO

User Image Doozio Posted - 6 days ago

@AnchorsAweigh once a 🧠 $dawn becomes 🧠⏰ they will slap the $halo on it and this drawdown shall be over.

User Image insiderbuyingselling Posted - 1 week ago

$HALO new insider selling: 20000 shares. http://insiderbuyingselling.com/?t=HALO

User Image Sean29md Posted - 1 week ago

$HALO Price/Earnings Ratios: 2024 Estimates 11.63 2025 Estimates 9.31 2026 Estimates 6.83 Forecast 12 Month Forward PEG Ratio 0.47 https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

User Image _bottomfishing_ Posted - 1 week ago

$MBOT $HALO $CGTX Analysts Are Bullish on Top Healthcare Stocks: https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-halozyme-halo-cognition-therapeutics-cgtx

User Image Aigner_Andreas Posted - 1 week ago

TD BUY $HALO at 38.72, Supp 38.61 Resis 41.32 R7 HiLo 61% T1Y 49 buy 2.3 DIV N/A #Halozyme T #stocks #trading #finance #market

User Image jiggs10 Posted - 2 weeks ago

@outofthisworld $HOLO not $HALO

User Image jiggs10 Posted - 2 weeks ago

@outofthisworld $113 easy like $HALO

User Image FannyPackin Posted - 2 weeks ago

$HALO constructive weekly, consolidating on da averages while they “turn up” 😎.. 50 in June/July, 📕 it..

User Image Sean29md Posted - 3 weeks ago

$HALO The top 5 science research-related stocks in 2024, as of the latest data available, are: Biomarin Pharmaceuticals Inc. (BMRN) - 43.0% 5-Year Average Annual EPS Forecast Halozyme Therapeutics, Inc. (HALO) - 25.0% 5-Year Average Annual EPS Forecast Incyte Corporation (INCY) - 22.5% 5-Year Average Annual EPS Forecast Genmab AS (GMAB) - 19.7% 5-Year Average Annual EPS Forecast Exelixis, Inc. (EXEL) - 19.0% 5-Year Average Annual EPS Forecast These stocks were chosen based on their forecasted earnings growth over the next five years, with a focus on those expected to grow EPS by an average of at least 9.5% per year over the next five years.

User Image uncleal Posted - 3 weeks ago

$HALO OOOPPS, now what?

User Image Howyoudoin Posted - 3 weeks ago

$HALO about to pop

User Image Doozio Posted - 3 weeks ago

Chop chop huckleberries slap a $halo on $cpng and $indv cuz its 🧠⏰ n ULBI ok.

User Image Sean29md Posted - 3 weeks ago

$HALO https://www.nasdaq.com/articles/the-3-best-biotech-stocks-to-buy-in-q2-2024

User Image Doozio Posted - 03/29/24

$lmnr $halo $box chop chop huckleberries….. n they shall continue to BRAG as da SEED grows in 🧠⏰ EH?

User Image Doozio Posted - 03/29/24

$BOX $HALO chop chop huckleberries wen 🧠⏰♾️😇📦?

User Image Doozio Posted - 03/29/24

Everything happens when it’s time. Chop chop huckleberries as a 🧠👀 with a $seed still planted becomes 🧠⏰ ♾️ with a $halo on a $box. 🧠⏰♾️😇📦 in 2020FOR

User Image Doozio Posted - 03/27/24

$iwm $xbi scanning da sim 👀 ing at all the chop chop huckleberries they are about to slap a 🧠⏰ $halo on.

User Image Quantumup Posted - 03/27/24

Oppenheimer🏁 $XERS OP/$5~believes successful comm exec around $XERS's 3 specialty Tx products will cont2drive top-line growth+disciplined spend should enable consistent profit w/in 2-3 yrs. Believes XP-8121 P2 data due mid-yr will⬆️confidence in pot $1B+ rev opp.. $amgn $regn $halo

User Image Nosh Posted - 03/27/24

$HALO This one is getting very tight...

User Image Doozio Posted - 03/27/24

Wen 🧠⏰ they 👋 the $halo on it emphatically???

User Image Sean29md Posted - 03/26/24

$HALO am I dreaming? Are my eyes deceiving me? Did LaBarre just convert some options and held onto the shares without selling a single one? This is welcomed news. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001159036/465f2965-ed25-4e96-9042-6b62a53e45e3.pdf

User Image TheOptionsOracleUSA Posted - 03/26/24

$HALO looks like it's ready to breakout. My target is $46 Thinking of buying the May 17 $40 and selling the $45

User Image Sean29md Posted - 1 month ago

$HALO what’s going on with Halozyme’s IR? emails unanswered, voice messages unreturned, requests to speak with executives ignored, multiple new trials, and no PR. The investors deserve better.

User Image FannyPackin Posted - 1 month ago

$APLS $SMTI $MIRM $HALO $IOVA biotech stocks with monthly charts that look 🧠 (& obviously NBIX & SRPT).. these & XBI 90% of my biotech positions but have a couple stinkers I won’t mention on this post 😂😅😅

User Image Sean29md Posted - 1 month ago

$HALO Another brand new study with Enhanze (first posted on 3/15/24). Phase 1 GSK/Viiv trial + Enhanze on a brand new antiviral: https://classic.clinicaltrials.gov/ct2/show/NCT06310551?term=Rhuph20&draw=4&rank=122

User Image GoddessWen Posted - 1 month ago

$APLS $ACAD $HALO $NTLA 👀

User Image DailyStocksPicks Posted - 1 month ago

Oversold Pick #5: Immunovant ($IMVT) might be perceived as oversold due to a combination of factors including optimistic analyst ratings with targets suggesting potential upside, recent financial and corporate updates indicating progress, and efforts to address safety concerns with its pipeline products, such as IMVT-1402, aimed at improving its competitive stance in the autoimmune disorder treatment landscape. Despite challenges, such as safety concerns with batoclimab, the company's strategic responses and the overall positive market sentiment reflect its potential for recovery and growth, suggesting that the current stock market performance may not fully reflect Immunovant's underlying value or future prospects. $RVMD, $KRYS, $HALO, $IOVA For More Details: https://youtu.be/Ff3pi-Ew5Og

Analyst Ratings
HC Wainwright & Co. Buy Apr 17, 24
Benchmark Buy Apr 16, 24
TD Cowen Outperform Feb 29, 24
JMP Securities Market Outperform Feb 21, 24
HC Wainwright & Co. Buy Feb 21, 24
Benchmark Buy Jan 19, 24
HC Wainwright & Co. Buy Jan 19, 24
JMP Securities Market Outperform Jan 18, 24
Goldman Sachs Neutral Jan 18, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Dec 12 Sell 40.14 20,000 802,800 151,911 12/13/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Dec 12 Option 12.65 20,000 253,000 161,911 12/13/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Oct 17 Sell 36.52 10,000 365,200 151,911 10/17/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Oct 17 Option 19.98 10,000 199,800 161,911 10/17/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Aug 29 Sell 42.69 30,000 1,280,700 623,666 08/31/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Aug 29 Option 13.87 30,000 416,100 633,666 08/31/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Aug 15 Sell 43.49 30,000 1,304,700 623,666 08/17/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Aug 15 Option 13.87 30,000 416,100 633,666 08/17/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Jun 21 Sell 36 10,000 360,000 141,911 06/22/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Jun 21 Option 18.41 10,000 184,100 151,911 06/22/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Apr 18 Option 18.41 10,000 184,100 151,911 04/19/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Apr 18 Sell 36 10,000 360,000 141,911 04/19/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 27 Sell 49.55 10,000 495,500 138,927 02/28/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 16 Sell 49.26 2,878 141,770 148,927 02/21/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 16 Option 0 6,112 151,805 02/21/23
LaBrosse Nicole SVP, CHIEF FINANCIAL.. SVP, CHIEF FINANCIAL OFFICER Feb 16 Sell 49.26 2,525 124,382 9,066 02/21/23
LaBrosse Nicole SVP, CHIEF FINANCIAL.. SVP, CHIEF FINANCIAL OFFICER Feb 16 Option 0 5,094 11,591 02/21/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Feb 16 Sell 49.26 11,061 544,865 633,666 02/21/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Feb 16 Option 0 21,010 644,727 02/21/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 15 Sell 48.39 10,000 483,900 143,477 02/17/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 15 Option 0 3,386 146,863 02/17/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Jan 17 Sell 50.66 10,000 506,600 143,137 01/18/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Dec 13 Option 14.66 30,000 439,800 597,177 12/15/22
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Dec 13 Sell 58.31 30,000 1,749,300 587,177 12/15/22
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Dec 13 Sell 58.67 10,000 586,700 153,137 12/13/22
Posard Matthew L. Director Director Dec 02 Sell 56.89 30,000 1,706,700 105,189 12/06/22
Torley Helen President and CEO President and CEO Nov 08 Option 14.66 50,000 733,000 587,160 11/08/21
Torley Helen President and CEO President and CEO Nov 08 Sell 40.02 50,000 2,001,000 537,160 11/08/21
Torley Helen President and CEO President and CEO Sep 07 Sell 42.63 50,000 2,131,500 537,160 09/07/21
Torley Helen President and CEO President and CEO Sep 07 Option 14.66 50,000 733,000 587,160 09/07/21
Torley Helen President and CEO President and CEO Jun 07 Option 14.66 50,000 733,000 587,160 06/07/21
Torley Helen President and CEO President and CEO Jun 07 Sell 39.66 50,000 1,983,000 537,160 06/07/21
Torley Helen President and CEO President and CEO May 11 Option 14.66 50,000 733,000 587,160 05/11/21
Kelley Kenneth J Director Director Mar 01 Sell 45.67 5,000 228,350 184,833 03/01/21
Torley Helen President and CEO President and CEO Mar 01 Option 14.66 50,000 733,000 587,160 03/01/21
Torley Helen President and CEO President and CEO Mar 01 Sell 46.03 50,000 2,301,500 537,160 03/01/21
Kelley Kenneth J Director Director Feb 01 Sell 48.39 5,000 241,950 189,833 02/01/21
Torley Helen President and CEO President and CEO Feb 01 Option 14.66 50,000 733,000 520,522 02/01/21
Torley Helen President and CEO President and CEO Feb 01 Sell 48.13 50,000 2,406,500 470,522 02/01/21
LaBarre Michael J. SVP, Chief Technical.. SVP, Chief Technical Officer Dec 21 Sell 42.9 12,000 514,800 122,800 12/21/20
Kelley Kenneth J Director Director Nov 27 Sell 41.38 19,671 813,986 266,711 11/27/20
Torley Helen President and CEO President and CEO Nov 25 Option 14.66 50,000 733,000 530,522 11/25/20
Torley Helen President and CEO President and CEO Nov 25 Sell 40.68 50,000 2,034,000 480,522 11/25/20
LaBarre Michael J. SVP, Chief Technical.. SVP, Chief Technical Officer Nov 20 Sell 38.64 12,000 463,680 134,800 11/20/20